Clinical Pregnancies and Live Births in women approaching ART: A follow-up analysis of 157 women after thrombophilia screening

E. Grandone, M. Villani, G. L. Tiscia, F. Dentali, D. Colaizzo, F. Cappucci, E. Chinni, W. Ageno, M. Margaglione

Research output: Contribution to journalArticle

Abstract

Introduction The role of thrombophilia screening and antithrombotic therapy in unselected women undergone Assisted Reproductive Technologies (ART) is largely unknown. Nonetheless, in many Countries infertile women undergo thrombophilia screening and/or antithrombotic therapy. Materials and Methods We carried out a follow-up study. The original sample (n = 1107) consisted of infertile women observed in 13 years. A cohort of 157 women with at least 1 cycle before thrombophilia test and 1 after test was investigated. All underwent thrombophilia screening; an antithrombotic treatment was prescribed in 216 out of 801 cycles. Clinical pregnancy and live birth rates were the main clinical objectives. Results Overall, 15 (9.6%) women carried thrombophilia. The Cox regression showed that LMWH alone or combined with ASA was significantly associated with the outcome "live birth" "live births" (p: 0.015, HR: 2.8, 95%CI: 1.2-6.6 for combined therapy), independently of the carriership of thrombophilia. Women with a lower number of attempts had a higher likelihood of delivering a live-born child using the combined therapy (p <0.001, HR: 0.7, 95%CI: 0.7-0.8), independently of the presence of thrombophilia. Conclusions A potential benefit of LMWH in improving number of live births, independently of the presence of thrombophilia, is suggested. Universal thrombophilia screening before ART is not useful to discriminate women with a worse pregnancy prognosis.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalThrombosis Research
Volume133
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Assisted Reproductive Techniques
Thrombophilia
Live Birth
Pregnancy
Low Molecular Weight Heparin
Therapeutics
Pregnancy Rate

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical Pregnancies and Live Births in women approaching ART : A follow-up analysis of 157 women after thrombophilia screening. / Grandone, E.; Villani, M.; Tiscia, G. L.; Dentali, F.; Colaizzo, D.; Cappucci, F.; Chinni, E.; Ageno, W.; Margaglione, M.

In: Thrombosis Research, Vol. 133, No. 2, 02.2014, p. 168-172.

Research output: Contribution to journalArticle

Grandone, E. ; Villani, M. ; Tiscia, G. L. ; Dentali, F. ; Colaizzo, D. ; Cappucci, F. ; Chinni, E. ; Ageno, W. ; Margaglione, M. / Clinical Pregnancies and Live Births in women approaching ART : A follow-up analysis of 157 women after thrombophilia screening. In: Thrombosis Research. 2014 ; Vol. 133, No. 2. pp. 168-172.
@article{8e417153d6964ab19026808717ccd6d8,
title = "Clinical Pregnancies and Live Births in women approaching ART: A follow-up analysis of 157 women after thrombophilia screening",
abstract = "Introduction The role of thrombophilia screening and antithrombotic therapy in unselected women undergone Assisted Reproductive Technologies (ART) is largely unknown. Nonetheless, in many Countries infertile women undergo thrombophilia screening and/or antithrombotic therapy. Materials and Methods We carried out a follow-up study. The original sample (n = 1107) consisted of infertile women observed in 13 years. A cohort of 157 women with at least 1 cycle before thrombophilia test and 1 after test was investigated. All underwent thrombophilia screening; an antithrombotic treatment was prescribed in 216 out of 801 cycles. Clinical pregnancy and live birth rates were the main clinical objectives. Results Overall, 15 (9.6{\%}) women carried thrombophilia. The Cox regression showed that LMWH alone or combined with ASA was significantly associated with the outcome {"}live birth{"} {"}live births{"} (p: 0.015, HR: 2.8, 95{\%}CI: 1.2-6.6 for combined therapy), independently of the carriership of thrombophilia. Women with a lower number of attempts had a higher likelihood of delivering a live-born child using the combined therapy (p <0.001, HR: 0.7, 95{\%}CI: 0.7-0.8), independently of the presence of thrombophilia. Conclusions A potential benefit of LMWH in improving number of live births, independently of the presence of thrombophilia, is suggested. Universal thrombophilia screening before ART is not useful to discriminate women with a worse pregnancy prognosis.",
author = "E. Grandone and M. Villani and Tiscia, {G. L.} and F. Dentali and D. Colaizzo and F. Cappucci and E. Chinni and W. Ageno and M. Margaglione",
year = "2014",
month = "2",
doi = "10.1016/j.thromres.2013.11.016",
language = "English",
volume = "133",
pages = "168--172",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Clinical Pregnancies and Live Births in women approaching ART

T2 - A follow-up analysis of 157 women after thrombophilia screening

AU - Grandone, E.

AU - Villani, M.

AU - Tiscia, G. L.

AU - Dentali, F.

AU - Colaizzo, D.

AU - Cappucci, F.

AU - Chinni, E.

AU - Ageno, W.

AU - Margaglione, M.

PY - 2014/2

Y1 - 2014/2

N2 - Introduction The role of thrombophilia screening and antithrombotic therapy in unselected women undergone Assisted Reproductive Technologies (ART) is largely unknown. Nonetheless, in many Countries infertile women undergo thrombophilia screening and/or antithrombotic therapy. Materials and Methods We carried out a follow-up study. The original sample (n = 1107) consisted of infertile women observed in 13 years. A cohort of 157 women with at least 1 cycle before thrombophilia test and 1 after test was investigated. All underwent thrombophilia screening; an antithrombotic treatment was prescribed in 216 out of 801 cycles. Clinical pregnancy and live birth rates were the main clinical objectives. Results Overall, 15 (9.6%) women carried thrombophilia. The Cox regression showed that LMWH alone or combined with ASA was significantly associated with the outcome "live birth" "live births" (p: 0.015, HR: 2.8, 95%CI: 1.2-6.6 for combined therapy), independently of the carriership of thrombophilia. Women with a lower number of attempts had a higher likelihood of delivering a live-born child using the combined therapy (p <0.001, HR: 0.7, 95%CI: 0.7-0.8), independently of the presence of thrombophilia. Conclusions A potential benefit of LMWH in improving number of live births, independently of the presence of thrombophilia, is suggested. Universal thrombophilia screening before ART is not useful to discriminate women with a worse pregnancy prognosis.

AB - Introduction The role of thrombophilia screening and antithrombotic therapy in unselected women undergone Assisted Reproductive Technologies (ART) is largely unknown. Nonetheless, in many Countries infertile women undergo thrombophilia screening and/or antithrombotic therapy. Materials and Methods We carried out a follow-up study. The original sample (n = 1107) consisted of infertile women observed in 13 years. A cohort of 157 women with at least 1 cycle before thrombophilia test and 1 after test was investigated. All underwent thrombophilia screening; an antithrombotic treatment was prescribed in 216 out of 801 cycles. Clinical pregnancy and live birth rates were the main clinical objectives. Results Overall, 15 (9.6%) women carried thrombophilia. The Cox regression showed that LMWH alone or combined with ASA was significantly associated with the outcome "live birth" "live births" (p: 0.015, HR: 2.8, 95%CI: 1.2-6.6 for combined therapy), independently of the carriership of thrombophilia. Women with a lower number of attempts had a higher likelihood of delivering a live-born child using the combined therapy (p <0.001, HR: 0.7, 95%CI: 0.7-0.8), independently of the presence of thrombophilia. Conclusions A potential benefit of LMWH in improving number of live births, independently of the presence of thrombophilia, is suggested. Universal thrombophilia screening before ART is not useful to discriminate women with a worse pregnancy prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84892368620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892368620&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2013.11.016

DO - 10.1016/j.thromres.2013.11.016

M3 - Article

C2 - 24321417

AN - SCOPUS:84892368620

VL - 133

SP - 168

EP - 172

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2

ER -